Convergence of Normal Stem Cell and Cancer Stem Cell Developmental Stage: Implication for Differential Therapies

Overview

Journal World J Stem Cells

Publisher Baishideng Publishing Group

Date 2011 Oct 19

PMID 22007273

Citations 6

Authors

Shengwen Calvin Li

Katherine L Lee

Jane Luo

Jiang F Zhong

William G Loudon

Affiliations

Soon will be listed here.

Abstract

Increased evidence shows that normal stem cells may contribute to cancer development and progression by acting as cancer-initiating cells through their interactions with abnormal environmental elements. We postulate that normal stem cells and cancer stem cells (CSC) possess similar mechanisms of self-renewal and differentiation. CSC can be the key to the elaboration of anti-cancer-based therapy. In this article, we focus on a controversial new theme relating to CSC. Tumorigenesis may have a critical stage characterized as a "therapeutic window", which can be identified by association of molecular, biochemical and biological events. Identifying such a stage can allow the production of more effective therapies (e.g. manipulated stem cells) to treat several cancers. More importantly, confirming the existence of a similar therapeutic window during the conversion of normal stem cells to malignant CSC may lead to targeted therapy specifically against CSC. This conversion information may be derived from investigating the biological behaviour of both normal stem cells and cancerous stem cells. Currently, there is little knowledge about the cellular and molecular mechanisms that govern the initiation and maintenance of CSC. Studies on co-evolution and interdependence of cancer with normal tissues may lead to a useful treatment paradigm of cancer. The crosstalk between normal stem cells and cancer formation may converge developmental stages of different types of stem cells (e.g. normal stem cells, CSC and embryonic stem cells). The differential studies of the convergence may result in novel therapies for treating cancers.

Citing Articles

Evidence for AJUBA-catenin-CDH4-linked differentiation resistance of mesenchymal stem cells implies tumorigenesis and progression of head and neck squamous cell carcinoma: a single-cell transcriptome approach.

Stucky A, Gao L, Sun L, Li S, Chen X, Park T Blood Genom. 2021; 5(1):29-39.

PMID: 34368804 PMC: 8346230. DOI: 10.46701/BG.2021012021106.

Extracellular Vesicle-Based Communication May Contribute to the Co-Evolution of Cancer Stem Cells and Cancer-Associated Fibroblasts in Anti-Cancer Therapy.

Valcz G, Buzas E, Sebestyen A, Krenacs T, Szallasi Z, Igaz P Cancers (Basel). 2020; 12(8).

PMID: 32824649 PMC: 7465064. DOI: 10.3390/cancers12082324.

TNF‑α promotes the malignant transformation of intestinal stem cells through the NF‑κB and Wnt/β‑catenin signaling pathways.

Zhao X, Ma L, Dai L, Zuo D, Li X, Zhu H Oncol Rep. 2020; 44(2):577-588.

PMID: 32627006 PMC: 7336517. DOI: 10.3892/or.2020.7631.

Cancer Niche as a Garbage Disposal Machine: Implications of TCM-Mediated Balance of Body-Disease for Treatment of Cancer.

Li S, Luo J, Lee K Online J Complement Altern Med. 2019; 1(3).

PMID: 31453571 PMC: 6709992. DOI: 10.33552/OJCAM.2019.01.000514.

Spatiotemporal switching signals for cancer stem cell activation in pediatric origins of adulthood cancer: Towards a watch-and-wait lifetime strategy for cancer treatment.

Li S, Kabeer M World J Stem Cells. 2018; 10(2):15-22.

PMID: 29531638 PMC: 5840533. DOI: 10.4252/wjsc.v10.i2.15.

References

Li S, Loudon W . A novel and generalizable organotypic slice platform to evaluate stem cell potential for targeting pediatric brain tumors. Cancer Cell Int. 2008; 8:9. PMC: 2474582. DOI: 10.1186/1475-2867-8-9. View

Drake N . Forty years on from Nixon's war, cancer research 'evolves'. Nat Med. 2011; 17(7):757. DOI: 10.1038/nm0711-757. View

Yurugi-Kobayashi T, Itoh H, Yamashita J, Yamahara K, Hirai H, Kobayashi T . Effective contribution of transplanted vascular progenitor cells derived from embryonic stem cells to adult neovascularization in proper differentiation stage. Blood. 2002; 101(7):2675-8. DOI: 10.1182/blood-2002-06-1877. View

Winkler F, Kozin S, Tong R, Chae S, Booth M, Garkavtsev I . Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004; 6(6):553-63. DOI: 10.1016/j.ccr.2004.10.011. View

Candeliere G, Rao Y, Floh A, Sandler S, Aubin J . cDNA fingerprinting of osteoprogenitor cells to isolate differentiation stage-specific genes. Nucleic Acids Res. 1999; 27(4):1079-83. PMC: 148289. DOI: 10.1093/nar/27.4.1079. View

Li S, Wang L, Jiang H, Acevedo J, Chang A, Loudon W . Stem cell engineering for treatment of heart diseases: potentials and challenges. Cell Biol Int. 2008; 33(3):255-67. DOI: 10.1016/j.cellbi.2008.11.009. View

Besson V, Smeriglio P, Wegener A, Relaix F, Nait Oumesmar B, Sassoon D . PW1 gene/paternally expressed gene 3 (PW1/Peg3) identifies multiple adult stem and progenitor cell populations. Proc Natl Acad Sci U S A. 2011; 108(28):11470-5. PMC: 3136256. DOI: 10.1073/pnas.1103873108. View

Elghetany M, Patel J . Assessment of CD24 expression on bone marrow neutrophilic granulocytes: CD24 is a marker for the myelocytic stage of development. Am J Hematol. 2002; 71(4):348-9. DOI: 10.1002/ajh.10176. View

Bagley R, Weber W, Rouleau C, Teicher B . Pericytes and endothelial precursor cells: cellular interactions and contributions to malignancy. Cancer Res. 2005; 65(21):9741-50. DOI: 10.1158/0008-5472.CAN-04-4337. View

10.

Strother D, Ashley D, Kellie S, Patel A, Thompson S, Heideman R . Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J Clin Oncol. 2001; 19(10):2696-704. DOI: 10.1200/JCO.2001.19.10.2696. View

11.

Yip S, Aboody K, Burns M, Imitola J, Boockvar J, Allport J . Neural stem cell biology may be well suited for improving brain tumor therapies. Cancer J. 2003; 9(3):189-204. DOI: 10.1097/00130404-200305000-00007. View

12.

Li H, Fan X, Kovi R, Jo Y, Moquin B, Konz R . Spontaneous expression of embryonic factors and p53 point mutations in aged mesenchymal stem cells: a model of age-related tumorigenesis in mice. Cancer Res. 2007; 67(22):10889-98. DOI: 10.1158/0008-5472.CAN-07-2665. View

13.

Li S, Zhong J . Twisting immune responses for allogeneic stem cell therapy. World J Stem Cells. 2010; 1(1):30-5. PMC: 2958105. DOI: 10.4252/wjsc.v1.i1.30. View

14.

Tyler M, Ulasov I, Sonabend A, Nandi S, Han Y, Marler S . Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther. 2008; 16(2):262-78. PMC: 2642530. DOI: 10.1038/gt.2008.165. View

15.

Li S, Gao Y, Tokuyama T, Yamamoto J, Yokota N, Yamamoto S . Genetically engineered neural stem cells migrate and suppress glioma cell growth at distant intracranial sites. Cancer Lett. 2007; 251(2):220-7. DOI: 10.1016/j.canlet.2006.11.024. View

16.

Loudon W, Abraham S, Hemingway L, Hemstreet G, Debault L . Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties. Cancer Res. 1988; 48(8):2184-92. View

17.

Balsam L, Wagers A, Christensen J, Kofidis T, Weissman I, Robbins R . Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature. 2004; 428(6983):668-73. DOI: 10.1038/nature02460. View

18.

Li S, Jin Y, Loudon W, Song Y, Ma Z, Weiner L . Increase developmental plasticity of human keratinocytes with gene suppression. Proc Natl Acad Sci U S A. 2011; 108(31):12793-8. PMC: 3150912. DOI: 10.1073/pnas.1100509108. View

19.

Dirks P . Brain tumour stem cells: the undercurrents of human brain cancer and their relationship to neural stem cells. Philos Trans R Soc Lond B Biol Sci. 2007; 363(1489):139-52. PMC: 2605491. DOI: 10.1098/rstb.2006.2017. View

20.

Daga A, Bottino C, Castriconi R, Gangemi R, Ferrini S . New perspectives in glioma immunotherapy. Curr Pharm Des. 2011; 17(23):2439-67. DOI: 10.2174/138161211797249206. View